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significance level of 0.05 was used for these analyses. RESULTS: Overall 7,261 en-
rolleeswere included in the analysis. Out of these, 187 (2.6%) hadHF at baseline and
1,075 (14.8%) experienced HF for the first time. Mean LOS was 4.29 (7.5) days but
increased significantly to 8.8 (17.6) days in case of new onset HF (  5.20.2,
p0.001) and to 9.7 (10.5) days if pre-existing HF was included as a major comor-
bidity (  6.00.7, p0.001) during index hospitalization. Hospitalization costs
(log-transformed) were associated with recording of new onset HF (  0.40.02,
p0.001) but not with reporting of pre-existing HF (  0.10.1, p0.1451) as a
comorbid condition during index hospitalization.CONCLUSIONS:Newonset of HF,
recorded as a major comorbid condition, in STEMI patients undergoing PCI exhib-
ited significant independent association with resource utilization including in-
creased length of stay and greater costs.
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OBJECTIVES: To evaluate persistence and compliance of fixed dose combinations
in comparison to unfixed dose combinations of angiotensin receptor blockers
(ARBs) in patients with hypertension in Germany. METHODS: This retrospective
study analyzed prescription data collected by general practitioners, using a longi-
tudinal database, the German IMS Disease Analyzer (DA). The DA database was
searched for patients with hypertension (ICD-10 code I10) who were initiated on
double or triple combinations of ARBs with hydrochlorothiazide (HCT) and/or am-
lodipine (AML) in the period 09/2008-08/2009with a follow-up of at least 12months.
Persistence was defined as proportion of patients who remained on their initially
prescribed therapy at 1 year. The difference between mean persistence values
(days) were calculated by using multiple regression analyses adjusted by age, gen-
der, region, insurance and co-morbidity. Compliance was measured indirectly
based on the medication possession ratio calculated as number of days supplied
within the refill interval in relation to the number of days in the refill interval.
RESULTS:Overall, 17,310 patientswere eligible for analysis: 35.7% on a fixed double
ARB combination, 33.0% on an unfixed double ARB combination, 25.9% on a semi-
fixed triple ARB combination, and 5.4% on an unfixed triple ARB combination.
Twelve months after first prescription persistence on unfixed versus semi-fixed
ARB/HCTAML triple combination was 32.7% and 46.7 % respectively, unfixed ver-
sus semi-fixed ARB/AMLHCT triple combination was 41.5% and 49.0% respec-
tively, unfixed versus fixed ARB/HCT double combination 23,8% and 41.1% respec-
tively, unfixed versus fixed ARB/AML double combination 27.5% and 44.4%
respectively. Mean days of persistence was higher in patients receiving fixed com-
binations (225.7-242.9) compared to unfixed combinations (163.6-228.0). Mean
compliance value with fixed combinations ranged between 72.0%-79.0%, with un-
fixed combinations between 71.5-76.2%. CONCLUSIONS: These real-life data con-
firms previous study results, that fixed combinations improve persistence in pa-
tients compared to unfixed combinations because of reduced pill burden.
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OBJECTIVES: Compare statin adherence, persistence, and health care costs among
patients in whom atorvastatin (AS), simvastatin (SS), rosuvastatin (RS), or prava-
statin (PS) was newly prescribed.METHODS: Study patients 18 years were iden-
tified betweenOctober 1, 2006-September 30, 2007, with aminimum12-month pre-
and 24-month post-index health plan eligibility from a managed care database. A
6-month washout period free of any statin use was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription and four cohortswere created based on index statins:
AS, SS, RS, and PS. These cohorts were matched according to propensity scores
based on patient clinical and demographic characteristics. Outcomes were com-
pared among matched cohorts during the 2-year post-index period, including ad-
herence to any statin (medication possession ratio0.8), time to any statin discon-
tinuation, and health care costs. RESULTS: After matching, 6185 patients were
obtained in each cohort and the baseline characteristics were balanced among
cohorts. Half of the patients were adherent to their statin therapy at 12 months
(52.2% for SS, 47.3% for AS, 48.6% for RS, and 49.7% for PS, P0.01), with further
decline at 24 months (43.1% for SS, 38.0% for AS, 39.2% for RS, and 38.5% for PS,
P0.01). Median time to any statin discontinuation within 24 months were less
than 1 year for all cohorts (SS: 308 days; AS: 250 days; RS: 266 days; PS: 301 days,
P0.01). The cohorts had slightly different 2-year health care costs (SS: $15,417; AS:
$16,826; RS: $15,874; PS: $15,481, P0.01) with the most difference attributable to
the lower drug costs (SS: $4460; AS: $5485; RS: $5424; PS: $4586, P0.01).
CONCLUSIONS: Patients had low adherence and persistence rates to statin ther-
apy. Patients initiating different statins had varying adherence and persistence
profiles, including 2-year health care costs.
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OBJECTIVES: The objective was to determine the impact of Medicare part D dough-
nut hole or the ‘coverage gap’ on medication compliance behavior and healthcare
resource utilization among Medicare beneficiaries taking statin medications.
METHODS: This was a retrospective cohort study using a 2007 5% National sample
of Medicare beneficiaries. Beneficiaries enrolled in the Part D programwith at least
1 prescription claim for statin were included in the study. Patients were classified
as continuers, switchers and discontinuers of statinmedications after reaching the
coverage gap. The primary outcomes of interest were average number of emer-
gency room (ER) visits, hospitalizations, out of pocket (OoP) costs and number of
prescriptions pre and post coverage gap. RESULTS: 131237 patients met the inclu-
sion criteria. All patients in the study sample were diagnosedwith hyperlipidemia,
and 8,251 patients were prescribedwith statins as a primary prevention treatment.
Of the beneficiaries taking statins, 65.8% were female; 80.71% white; 10.91% black
and themean age was 71.9 (12.0) years. Overall, 24.3% of statin users reached the
coverage gap in 2007, with 10.2% reaching the gap by March, 42.0% by June, and
74.4% by September. Within 90 days after reaching the gap, 74.2% of statin users
continued using their statin medication, 1.0% switched to a different statin medi-
cation, and 24.8% discontinued use of statins. After reaching the coverage gap, the
average number of ER visits/month increased from 0.24 to 0.25 and the average OoP
costs/month increased from $58.51 to $104.03. CONCLUSIONS: The results suggest
an overall negative impact of the Medicare part D coverage gap on enrollee health,
adherence to statin medications, number of hospitalizations, emergency depart-
ment visits and out of pocket expenses incurred by beneficiaries. The disruption of
the coverage gap on the quality of care is demonstrated by the large percentage of
statin users discontinuing therapy.
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OBJECTIVES:To evaluate treatment compliance and persistence in patients receiv-
ing fixed combinations compared to patients receiving unfixed combinations with
olmesartan medoxomil for hypertension treatment in Germany. METHODS: This
retrospective study analyzed prescription data collected by general practitioners,
using a longitudinal database, the German IMS Disease Analyzer (DA). The DA
database was searched for patients with hypertension (ICD-10 code I10) who were
initiated on double or triple combinations of olmesartan medoxomil with hydro-
chlorothiazide and/or amlodipine in the period 09/2008-08/2009with a follow-up of
at least 12 months. Persistence was defined as proportion of patients who re-
mained on their initially prescribed therapy at 1 year. The difference between
mean persistence values (days) were calculated by using multiple regression anal-
yses adjusted by age, gender, region, insurance and co-morbidity. Compliance was
measured indirectly based on the medication possession ratio calculated as num-
ber of days suppliedwithin the refill interval in relation to thenumber of days in the
refill interval. RESULTS: In total, 7,360 patients were eligible for analysis, 58.0%
were treated with a fixed or semi-fixed combination of olmesartan and 42.0% with
a dual or triple unfixed combination of olmesartan. After 12 months following the
first prescription, fixed or semi-fixed combinations had a higher rate of persistence
(43.4%-50.2%) compared to dual or triple unfixed combinations (25.0%-35.8%).Mean
duration of persistence was higher in patients receiving dual or triple fixed or
semi-fixed combinations (222.5-242.7 days) compared to patients receiving unfixed
combinations (183.6-205.0 days). Mean compliance value with olmesartan in all
combinations ranged between 70.0% 80.0%. CONCLUSIONS: Overall, persistence
is increased in patients receiving fixed combinations of olmesartan in comparison
to free combinations. These real-life data confirms previous study results, that
persistence of fixed combinations in comparison to unfixed combinations is im-
proved because of reduced pill burden.
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OBJECTIVES: The impact of health behaviors (e.g., medication adherence) on out-
comes (e.g., hospitalizations) has been widely explored in literature, but few stud-
ies have evaluated the reverse association. We investigated the impact of cardio-
vascular disease (CVD) hospitalizations on changes in adherence to
antihypertensive (AH) drugs.METHODS:Maryland Medicaid claims data from Jan-
uary 2001 to June 2006 were analyzed. The index date for patients with a CVD
hospitalization was the admission date of the first observed CVD-related hospital-
ization. Matched controls had the same index date as index patients. Proportion of
days covered (PDC) was used to measure medication adherence (adherence:
PDC80%). Patients with and without a CVD hospitalization were matched 1:1, on
the first pharmacy claim (6month) of any AH drugs recorded in the database, age
(5 years), gender, race, number of drugs taken in the 6-month pre-index period
(1 drug), and adherence rate to AH drugs in the 6-month pre-index period (5%
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PDC). The outcome was adherence to AH drugs in the 6-month post-index period.
Logistic regression analysis was conducted to explore the impact of CVD hospital-
izations on changes in adherence to AH drugs. RESULTS: There were 1332 patients
with AH drugs. Patients with a CVD hospitalizationwere 2.9 times (95% Confidence
Interval: 2.1-3.9) more likely to be adherent in the 6-month post-index period com-
pared to control patients. Among patients with a CVD hospitalization, the propor-
tion of patients who were non-adherent to AH drugs in the 6-month post-index
period was 30.6%. CONCLUSIONS: Patient adherence to AH drugs improved after a
CVD hospitalization, but there was still a substantial proportion of patients who
were non-adherent after that hospitalization. Counseling patients on medication
adherence during their hospitalizationmay be an effective way for improving their
adherence following discharge.
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OBJECTIVES: To estimate patient adherence with once-a-day (QD) vs. twice-a-day
(BID) chronic medications following hospital discharge for ACS. METHODS: A ret-
rospective cohort study of patients discharged between 1/1/2007 and 4/30/2009
with an ACS diagnosis was performed using a large hospital and pharmacy claims
dataset. Two chronic medications dispensed for QD and BID utilization, carvedilol
andmetformin, were analyzed for adherencemeasures [persistency, days on ther-
apy, compliance (medication possession ratio, MPR), total # of dispensed prescrip-
tions, gap (days) between refills] over a 12 month post-index period. Included pa-
tients had first dispensed prescription of carvedilol or metformin within 60 days of
discharge (index prescription) and had Rx activity for any drug  12 months post-
index. Persistence was defined as percentage of patients without a therapy lapse
of  30 days from last dispensed day’s supply. RESULTS: Persistency with carve-
dilol QD vs. BID (N168 vs. 2086) at 6 months was 44.0% vs 43.7% and at 12 months
was 24.4% vs. 25.5%. Persistency with metformin QD vs. BID (N136 vs. 614) at 6
months was 50.7% vs 53.7% and at 12 months was 28.7 vs. 35.0%. The average days
on therapy for carvedilol QD vs. BID at 6 months was 120.5 vs. 121.9 and at 12
months was 196.7 vs. 203.0. Average days on therapy for metformin QD vs. BID at 6
monthswas 123.6 vs. 136.2 and at 12monthswas 206.1 vs. 237.7. Compliance (MPR)
with QD vs. BID carvedilol at 12months was 84.2% vs 80.7% and for metformin was
77.6% vs 81.6%. Additional adherence metrics were consistent for QD vs. BID
dosing. CONCLUSIONS: In ACS patients, no clinically meaningful differences on
adherence measures were observed between QD versus BID dosing formulations
over a 12 month follow-up period. Results indicate potential opportunities to im-
prove persistency with chronic therapies in ACS patients.
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OBJECTIVES: Justification for the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) demonstrated a statin benefit for primary pre-
vention. However, real-world patientsmay not exhibit medication persistence and
adherence seen in the trial. We described persistence and adherence of first-time
statin users. METHODS: A 10% random sample of the IMS LifeLink Health Plan
Claims Database was used to obtain prescription claims records for adult (18
years) first-time statin users with continuous health plan eligibility 12 months
prior and 32 months after the index statin prescription between July 1, 1997 and
December 31, 2008. Persistence and adherence were measured during the 24
months after statin initiation. Patients were persistent if gaps in statin use did not
exceed 180 consecutive days. Adherence was measured as the medication posses-
sion ratio (MPR) during the period of persistence. Persistence groups were catego-
rized as ‘short’ (9 months), ‘intermediate’ (9-16 months) and ‘long’ (17months)
and compared using ANOVA. RESULTS: Among 26,530 new statin users, the mean
length of persistence was 17months. The proportions in each persistence category
were: 21% ‘short’, 12% ‘intermediate’ and 68% ‘long’. 32% were persistent for 24
months or more, as compared to 75% of JUPITER patients taking medication after
the median 1.9 year study period. Mean MPR of the ‘intermediate’ and ‘short’ per-
sistence categories were similar (0.70 vs. 0.69, P.15), but lower than the overall
mean MPR of 0.80. Mean MPR was greatest in the ‘long’ persistence category (0.85,
P.0001) and was higher than the overall mean MPR. CONCLUSIONS: Persistence
and adherence measure two different but critical concepts: the length of time
patients use statins and their adherence to the statin regimen during that period,
which we found to vary. Extrapolating the primary prevention benefits of statins
must account for both measures, as they differ from clinical trials to practice.
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OBJECTIVES: Several studies have demonstrated that higher patient out-of pocket
cost may result in lower medication adherence. The purpose of this study was to
measure Medication Possession Ratio (MPR) among patients newly-prescribed a
brand or generic statin medication in a managed Medicaid plan and a commercial
health plan. METHODS: We conducted a retrospective analysis using pharmacy
claims data to identify patients who were new to statin treatment (no pharmacy
claim for a lipid-lowering medication in the previous 12 months). Patients were
categorized based on their index medication. We used a Robust linear regression
model to determine predictors of adherence. RESULTS: A total of 738 commercial
patients and 2175 Medicaid patients were included. Sixty percent of Medicaid pa-
tients and 49% of commercial patients initiated therapywith a genericmedication.
Average patient out-of-pocket cost for commercial plan patients was $9/month for
generic and $15/month for brand. Medicaid patients had no copayment for generic
or brand medications. In the commercial plan, there was no significant difference
in MPR between patients who initiated therapy with generic or brand statins (MPR
0.75 vs. 0.73, respectively). In the Medicaid plan, MPR was significantly higher
among patients who started on generic medications (0.69 vs. 0.63). In robust linear
regression, MPR was significantly related to age, number of comorbidities and ge-
neric use. After we adjusted MPR for age and comorbidities, MPR remained signif-
icantly higher in the Medicaid generic group. CONCLUSIONS: Medicaid patients
prescribed a generic statin as initial therapy were more adherent than those pre-
scribed a brand, despite having no copayment for generic or brand medications.
This differencewas not present among commercial plan patientswho had a higher
cost share for brandmedications. This suggests that additional research is needed
to identify non-financial barriers to adherence.
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OBJECTIVES: To examine statin adherence and persistence among patients receiv-
ing treatment for secondary prevention of coronary heart disease (CHD) at US
Military Treatment Facilities (MTF) within the Department of Defense (DoD).
METHODS: Retrospective cohort study utilizing the DoD Military Health System
database to examine 21,053 TRICARE beneficiaries between 18-75 years of age,
receiving medical services for a primary CHD event at an MTF between January 1,
2004 and December 31, 2008. Drug adherence was measured using the Medication
Possession Ratio (MPR) at 6, 12 and 18 months. Persistence was measured as dura-
tion of statin-therapy based on35-day refill gap. Covariates included age, gender,
comorbidities, drug-switching and dosage titration. Logistic regression was con-
ducted to assess predictors of adherence [95% Confidence-Intervals]. RESULTS:
The CHD cohort (N21,053) was 74% male with a mean age of 57.4(SD8.8) years.
Overall mean MPR was 89%(SD22) at month six (M6), 84%(SD25) at 12-months
(M12), and 81%(SD26.4) after 18-months (M18). Approximately 80% of patients
were adherent (MPR80%)with statin-therapy atM6which declined to 71% atM12,
and 69% at the end of M18 (p.001). Older male patients with hyperlipidemia were
more adherent. Adjusting for covariates, patients were more likely to be adherent
at M6, M12, and M18 that switched statins (OR1.87[1.65-2.13],1.3[1.24-1.46], and
1.07[1.00-1.15]) or had at least one titration adjustment (OR2.99[2.62-3.40],1.86
[1.72-2.01], and 1.54[1.44-1.65]) compared to patients with no therapeutic adjust-
ments. Overall mean persistence to statins was 322 days. Patients experiencing
35-day refill gap increased from 34% to 53% to 63% at 6, 12, and 18-months
respectively. CONCLUSIONS: This study showed statin adherencewas high among
DoD patients receiving medical care at MTFs for secondary prevention of CHD
during the first 6-months. Adherence and persistence, however, declined bymonth
12. Improved patient adherence was associated with closer monitoring of pre-
scribed therapy, as seen among patients who were titrated or switched statins.
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OBJECTIVES: A recent study by our team indicated that approximately 13% of
prescribed venous thromboembolism (VTE) prophylactic doses are not adminis-
tered. The goal of this study was to determine documented reasons and describe
the distribution patterns for non-administered VTE prophylaxis doses.METHODS:
We conducted a retrospective review of electronic medication administration re-
cords using our computerized physician order entry system. The study included
hospitalized patients aged 18 years or older who were ordered pharmacologic VTE
prophylaxis from December 1, 2007 through June 30, 2008. RESULTS: A total of
108,533 VTE prophylaxis doses were ordered for 8,607 patients. 12.8% of ordered
doses were not administered. Non-administration rates varied by patient floor
from 4.8% to 33.9%. Approximately 53% of doses that were not administered (6.8%
of all doses) were documented as patient refusal – the most common documented
reason for non-administration of VTE prophylaxis by a widemargin. Patient refus-
als varied greatly by nursing unit, ranging from less than 1% to 19% of ordered
doses. Patient refusals were highly concentrated on certain nursing units; 5 nurs-
ing units accounted for two-thirds of all refused doses. A small number of patients
accounted for the vastmajority of refused doses; 11% of patients who refusedmore
than 1 dose accounted for nearly 87% of all refused doses. CONCLUSIONS: Patient
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